These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31084943)

  • 21. Sickling-induced binding of immunoglobulin to sickle erythrocytes.
    Green GA; Kalra VK
    Blood; 1988 Mar; 71(3):636-9. PubMed ID: 3278749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
    Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR
    Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of isotope exchange based mass spectrometry to understand the mechanism of inhibition of sickle hemoglobin polymerization upon oxygenation.
    Das R; Mitra A; Bhat V; Mandal AK
    J Struct Biol; 2017 Jul; 199(1):76-83. PubMed ID: 28465180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hemoglobin S as the cause of primary hyperviscosity of the blood].
    Mosca A; Samaja M; Niggeler M; Rossi-Bernardi L
    Ric Clin Lab; 1983; 13 Suppl 3():115-20. PubMed ID: 6672990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sickling times of individual erythrocytes at zero Po2.
    Zarkowsky HS; Hochmuth RM
    J Clin Invest; 1975 Oct; 56(4):1023-34. PubMed ID: 239967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous polymerization and adhesion under hypoxia in sickle cell disease.
    Papageorgiou DP; Abidi SZ; Chang HY; Li X; Kato GJ; Karniadakis GE; Suresh S; Dao M
    Proc Natl Acad Sci U S A; 2018 Sep; 115(38):9473-9478. PubMed ID: 30190429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rate of deoxygenation modulates rheologic behavior of sickle red blood cells at a given mean corpuscular hemoglobin concentration.
    Kaul DK; Liu XD
    Clin Hemorheol Microcirc; 1999; 21(2):125-35. PubMed ID: 10599596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of fetal hemoglobin on the sickling dynamics of SS erythrocytes.
    Sewchand LS; Johnson CS; Meiselman HJ
    Blood Cells; 1983; 9(1):147-66. PubMed ID: 6190521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro exposure to hydroxyurea reduces sickle red blood cell deformability.
    Huang Z; Louderback JG; King SB; Ballas SK; Kim-Shapiro DB
    Am J Hematol; 2001 Jul; 67(3):151-6. PubMed ID: 11391710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utilization of monoclonal-antibody-based assay (HemoCard in screening for and differentiating between genotypes of sickle cell disease and other hemoglobinopathies.
    Schultz JC
    J Clin Lab Anal; 1995; 9(6):366-74. PubMed ID: 8587004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determination of deoxyhemoglobin S polymer in sickle erythrocytes upon deoxygenation.
    Noguchi CT; Torchia DA; Schechter AN
    Proc Natl Acad Sci U S A; 1980 Sep; 77(9):5487-91. PubMed ID: 6933568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice.
    Shrestha A; Chi M; Wagner K; Malik A; Korpik J; Drake A; Fulzele K; Guichard S; Malik P
    Blood Adv; 2021 May; 5(9):2385-2390. PubMed ID: 33944896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High expression of human beta S- and alpha-globins in transgenic mice: hemoglobin composition and hematological consequences.
    Fabry ME; Nagel RL; Pachnis A; Suzuka SM; Costantini F
    Proc Natl Acad Sci U S A; 1992 Dec; 89(24):12150-4. PubMed ID: 1465454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Established and experimental treatments for sickle cell disease.
    De Franceschi L; Corrocher R
    Haematologica; 2004 Mar; 89(3):348-56. PubMed ID: 15020275
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Irreversibly sickled erythrocytes in sickle cell anemia: a quantitative reappraisal.
    Rodgers GP; Noguchi CT; Schechter AN
    Am J Hematol; 1985 Sep; 20(1):17-23. PubMed ID: 4025318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. βT87Q-Globin Gene Therapy Reduces Sickle Hemoglobin Production, Allowing for
    Demirci S; Gudmundsdottir B; Li Q; Haro-Mora JJ; Nassehi T; Drysdale C; Yapundich M; Gamer J; Seifuddin F; Tisdale JF; Uchida N
    Mol Ther Methods Clin Dev; 2020 Jun; 17():912-921. PubMed ID: 32405513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sickling in vitro of reticulocytes from patients with sickle cell disease at venous oxygen tension.
    Horiuchi K; Onyike AE; Osterhout ML
    Exp Hematol; 1996 Jan; 24(1):68-76. PubMed ID: 8536795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overview of pathophysiology and rationale for treatment of sickle cell anemia.
    Rodgers GP
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):2-7. PubMed ID: 9317195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of sickling on ion transport. I. Effect of sickling on potassium transport.
    TOSTESON DC; CARLSEN E; DUNHAM ET
    J Gen Physiol; 1955 Sep; 39(1):31-53. PubMed ID: 13252234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iron deficiency and sickle cell anemia.
    Rao KR; Patel AR; Honig GR; Vida LN; McGinnis PR
    Arch Intern Med; 1983 May; 143(5):1030-2. PubMed ID: 6679216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.